TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

23 Dec 2024 15:04:36 By NetDania Notify

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

20 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

20 Dec 2024 11:00:15 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

18 Dec 2024 09:01:35 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

17 Dec 2024 08:45:20 By NetDania Notify

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

17 Dec 2024 06:30:00 By Nasdaq GlobeNewswire

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

05 Dec 2024 17:00:00 By Nasdaq GlobeNewswire

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

04 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

25 Nov 2024 17:00:00 By Nasdaq GlobeNewswire

Teva to Present at the Jefferies London Healthcare Conference

08 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

06 Nov 2024 08:46:07 By NetDania Notify

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

06 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

01 Nov 2024 14:05:00 By Nasdaq GlobeNewswire

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

01 Nov 2024 14:00:00 By Nasdaq GlobeNewswire

Teva Statement on European Commission Decision; Company to Appeal

31 Oct 2024 06:29:54 By Nasdaq GlobeNewswire

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

22 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

08 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

03 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

01 Oct 2024 07:29:04 By Nasdaq GlobeNewswire